Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-Naïve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir

Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

(2013) Eric S. Daar   ANNALS OF INTERNAL MEDICINE

Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study)

(2011) D Podzamczer et al.   HIV MEDICINE

Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities

(2010) Anatol Kontush et al.   CURRENT OPINION IN LIPIDOLOGY

Nevirapine Increases High-Density Lipoprotein Cholesterol Concentration by Stimulation of Apolipoprotein A-I Production

(2009) Remco Franssen et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women

(2009) Samia Mora et al.   CIRCULATION

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens

(2009) Anuradha Ganesan et al.   AIDS Research and Therapy

Lipoprotein changes in HIV-infected antiretroviral-naïve individuals after starting antiretroviral therapy: ACTG Study A5152s

(2008) James H. Stein et al.   Journal of Clinical Lipidology

High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk

(2008) Wim A. van der Steeg et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial

(2007) Bela F. Asztalos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL